[en] Acute rejection after kidney transplantation is a major cause
of allograft dysfunction and can lead to rapid loss of graft
function despite anti-rejection therapy. Even when kidney
function initially recovers, acute rejection is associated with
an increased risk of long-term graft failure (1). Acute
rejection is, accordingly, a well-established surrogate
endpoint for long-term outcomes. High-quality evidence
has shown that induction therapy with a biological agent
lowers the risk of acute rejection, and it is therefore widely
administered as part of the early immunosuppressive
regimen (2,3). In recipients at low immunological risk (i.e.
patients with no previous exposure to human leukocyte
antigens [HLA]) either lymphocyte-depleting polyclonal
Disciplines :
Surgery
Author, co-author :
Hellemans, R
Hazzan, M
Durand, D
Mourad, G
Lang, P
Kessler, M
Charpentier, B
Touchard, G
Berthoux, F
Merville, P
Ouali, N
SQUIFFLET, Jean-Paul ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Wu O, Levy AR, Briggs A, Lewis G, Jardine A,. Acute rejection and chronic nephropathy: A systematic review of the literature. Transplantation 2009; 87: 1330-1339.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9: S1-155.
Noël C, Abramowicz D, Durand D, et al., Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20: 1385-1392.
Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D,. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-1977.
Soulillou JP, Cantarovich D, Le Mauff B, et al., Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175-1182.
Kriaa F, Hiesse C, Alard P, et al., Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: Results of a randomized study. Transplant Proc 1993; 25: 817-819.
Lebranchu Y, Bridoux F, Büchler M, et al., Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56.
Kyllönen LE, Eklund BH, Pesonen EJ, Salmela KT,. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: Efficacy and safety. Transplantation 2007; 84: 75-82.
Racusen LC, Solez K, Colvin RB, et al., The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2011. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2013. Available at: http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2011.pdf Accessed June 23, 2014.
Gondos A, Döhler B, Brenner H, Opelz G,. Kidney graft survival in Europe and the United States: Strikingly different long-term outcomes. Transplantation 2013; 95: 267-274.
Knoll GA,. Proteinuria in kidney transplant recipients: Prevalence, prognosis, and evidence-based management. Am J Kidney Dis 2009; 54: 1131-1144.
Kim MJ, Tsinalis D, Franz S, et al., ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: A prospective randomized pilot trial. Ann Transplant 2008; 13: 21-27.
Popat R, Syed A, Puliatti C, Cacciola R,. Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants. Transplantation 2014; 97: 1161-1165.
Brennan DC, Schnitzler MA,. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 2008; 359: 1736-1738.
Opelz G, Naujokat C, Daniel V, Terness P, Döhler B,. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227-1233.
Morgan RD, O'Callaghan JM, Knight SR, Morris PJ,. Alemtuzumab induction therapy in kidney transplantation: A systematic review and meta-analysis. Transplantation 2012; 93: 1179-1188.
Hanaway MJ, Woodle ES, Mulgaonkar S, et al., INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909-1919.
Iyer HS, Jackson AM, Zachary AA, Montgomery RA,. Transplanting the highly sensitized patient: Trials and tribulations. Curr Opin Nephrol Hypertens 2013; 22: 681-688.
Montgomery RA, Lonze BE, King KE, et al., Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
